Business Overview
Allchem lifescience is an Indian manufacturer of active pharmaceutical ingredient (API) intermediates and specialty chemicals, with a strong presence in both domestic and international markets. It specializes in producing key starting materials (KSMs), generic API intermediates, and fine chemicals, serving as a trusted partner to leading pharmaceutical and chemical companies. Over the years, the company has developed the capability to manufacture 263 products, showcasing deep expertise in diverse organic chemistries and a strong commitment to quality, innovation, and sustainable growth.
Allchem IPO Size
Objects of Issue
- Repayment and/ or pre-payment, in full or part, of certain borrowings availed by the Company.
- General corporate purposes
Allchem IPO Financial Performance
(Rs. in crores)
| Particulars | Sep-24 | Mar-24 | Mar-23 | Mar-22 |
|---|---|---|---|---|
| Revenue from Operations | 78.45 | 137.42 | 105.72 | 108.10 |
| Profit after Tax | 10.89 | 23.41 | 17.99 | 14.14 |
| Net Worth | 90.74 | 79.89 | 56.49 | 38.58 |
| Total Borrowing | 106.90 | 104.97 | 97.17 | 49.53 |
| Total Assets | 246.30 | 224.65 | 186.68 | 124.02 |
| NAV per share (in ₹) | 11.86 | 10.44 | 7.38 | 6.12 |
| EPS - Basic (in ₹) | 1.42 | 3.06 | 2.36 | 2.24 |
Key Performance Indicators (KPIs)
EBITDA
38.05%
PAT
17.03%
ROC
34.33%
ROCE
22.87%
Debt to Equity
1.31
- All the data pertains to FY 2023-24.
- PE, PB, and market capitalization are calculated based on the Upper Price Band.
Promoter Holding
Promoter
100.00%
Public
0.00%
Management
Registrar & Lead Managers
Registrar
MUFG Intime India
Lead Managers (1)
Company Details
Name: Allchem Lifescience Limited
Address: Block No. 1088/B/P, 1088-A,
Lamdapura Road, Village
Manjusar, Tal-Savli,
Vadodara, Vadodara, Gujarat
391775, India
Number: 9574722211
Email: investor@allchemlifescience
Website: https://www.allchemlifescience.com/
Delete Comment?
Are you sure you want to delete this comment? This action cannot be undone.
Discussion
Join the discussion!
Log In to CommentNo comments yet. Be the first to share your thoughts!